Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Biochem Pharmacol. 2010 Jul 21;80(9):1317–1325. doi: 10.1016/j.bcp.2010.07.022

Fig. 6.

Fig. 6

Relationship between tumor AGT content and resistance to Onrigin™ in vivo. EMT6/wt, EMT6/mAGT4 and EMT6/mAGT10 cells were implanted into the flank of BALB/c mice. Onrigin™ treatment was initiated when average tumor volumes reached 100 to 120 mm3 (Day 1). Non-transfected (wild-type) and empty vector transfected EMT6 tumors exhibited equal sensitivity to Onrigin™ and thus only results with wild-type EMT6 tumors are shown.